Adding MEK/ERK inhibitors to various chemotherapeutic agents [47], including ALDH1A inhibitor [18] and Src inhibitor [22], has been suggested as a way to overcome ovarian cancer therapy resistance. Here, SRC is linked to ovarian carcinoma.